MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS...
Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class...
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) --...
Exhibit A Exhibit A Exhibit B Exhibit B Exhibit C Exhibit C Migraines affect over 37 million Americans, according to...
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study...
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
– Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy – – Phase 1/2...
SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage...
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Grant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property PortfolioNEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Anavex...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s...
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development...
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
WINNIPEG, MB / ACCESSWIRE / November 21, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
WASHINGTON, DC and MONTEVIDEO, URUGUAY / ACCESSWIRE / November 21, 2023 / The MMJ International Holdings, MMJ BioPharma Cultivation, MMJ...
VANCOUVER, BC / ACCESSWIRE / November 21, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to...